CXCR4 and acute myeloid leukemia: Repeated administration of the T22-GFP-H6-Auristatin nanoconjugate (NC) in a CXCR4+ THP-1 AML mouse model achieved potent anticancer activity, by significantly reducing the leukemic cell burden in the bone marrow and circulating blood, and by inducing a potent blockade of leukemic cell spread to extramedullar organs.